BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...I data this half from menin inhibitor SNDX-5613...
BioCentury | May 8, 2020
Finance

Follow-on market poised for comeback, at least temporarily

...69%) to $19.50 on April 28 following the presentation of promising Phase I/II data from SNDX-5613...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

...to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613...
...responses in two out of three patients with acute leukemias that harbor an MLL1 rearrangement. SNDX-5613...
BioCentury | Apr 29, 2020
Product Development

April 28 Quick Takes: Syndax gains on leukemia data; plus Supernus, Neurocrine, Avadel, Insilico-Astellas, Innovent-Lilly, Chimerix

...to $19.50 on Tuesday after presenting initial data from the Phase I/II AUGMENT-101 trial of SNDX-5613...
BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

...application pending in China for its use against coronavirus (see “O’Day on Remdesivir” ). Syndax’s SNDX-5613...
...Pharmaceuticals Inc. (NASDAQ:SNDX) team showed in a January Science article that a structural analog of SNDX-5613...
...the inhibitor of the menin-MLL1 interaction the team described in December in Cancer Cell . SNDX-5613...
BioCentury | Dec 13, 2019
Preclinical News

Dec. 12 Preclinical Quick Takes: POC for Aptose blood cancer candidate, plus Penn-Acorn AI, Neurimmune-Biogen and Syndax

...support development of menin inhibitor SNDX-5613 from Syndax Pharmaceuticals Inc. (NASDAQ:SNDX). The molecule, a close SNDX-5613...
...In patient-derived xenograft mouse models of acute leukemias, the compound eradicated disease and extended survival. SNDX-5613...
BioCentury | Mar 15, 2019
Clinical News

Syndax pauses entinostat-PD-1/PD-L1 combo program

...advancing entinostat, an oral HDAC inhibitor, in hormone receptor-positive breast cancer and on preclinical compound SNDX-5613...
Items per page:
1 - 7 of 7